Historial de ingresos, beneficios y flujo de caja según los estados financieros oficiales.
Vertex Pharmaceuticals Incorporated opera como una empresa de biotecnología en Estados Unidos, Europa e internacionalmente. La empresa ofrece medicamentos transformadores para personas con enfermedades graves centrándose en mercados especializados, como la fibrosis quística (FQ), la anemia de células falciformes (SCD), la beta talasemia dependiente de transfusiones (TDT) y el dolor agudo.
Traducido automáticamente
Ver gráficos interactivos y estados completos → Modelo de valoración (DCF) →
| Cuenta de resultados | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 | 2007-12-31 | 2006-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ingresos totales | $12.6B | $12.1B | $11.0B | $9.9B | $8.9B | $7.6B | $6.2B | $4.2B | $3.0B | $2.5B | $1.7B | $1.0B | $580M | $1.2B | $1.5B | $1.4B | $143M | $102M | $176M | $199M | $216M |
| Beneficio bruto | $10.9B | $10.3B | $9.5B | $8.6B | $7.8B | $6.7B | $5.5B | $3.6B | $2.6B | $2.2B | $1.5B | $907M | $519M | $1.1B | $1.2B | $1.3B | $131M | $88M | $160M | $185M | $204M |
| % de margen bruto | 86.0% | 85.0% | 86.1% | 87.2% | 87.9% | 88.1% | 88.1% | 86.8% | 86.6% | 88.9% | 87.6% | 87.8% | 89.5% | 89.2% | 81.7% | 94.3% | 91.1% | 86.1% | 91.1% | 93.0% | 94.4% |
| Ingresos operativos (EBIT) | $4.9B | $4.8B | ($233M) | $3.8B | $4.3B | $2.8B | $2.9B | $1.2B | $635M | $123M | $10M | ($469M) | ($692M) | ($903M) | $2M | $114M | ($696M) | ($613M) | ($463M) | ($420M) | ($229M) |
| % de margen operativo | 38.6% | 39.4% | -2.1% | 38.8% | 48.2% | 36.7% | 46.0% | 28.8% | 20.8% | 5.0% | 0.6% | -45.4% | -119.3% | -74.5% | 0.1% | 8.1% | -485.5% | -601.1% | -263.6% | -210.9% | -105.9% |
| Ingresos netos | $4.4B | $4.0B | ($536M) | $3.6B | $3.3B | $2.3B | $2.7B | $1.2B | $2.1B | $263M | ($112M) | ($558M) | ($739M) | ($445M) | ($107M) | $30M | ($755M) | ($642M) | ($460M) | ($391M) | ($207M) |
| % de margen neto | 34.9% | 32.7% | -4.9% | 36.7% | 37.2% | 30.9% | 43.7% | 28.3% | 68.8% | 10.6% | -6.6% | -54.1% | -127.2% | -36.7% | -7.0% | 2.1% | -526.3% | -628.7% | -262.0% | -196.6% | -95.6% |
| EBITDA | $5.4B | $4.9B | $486M | $4.6B | $4.4B | $2.9B | $3.3B | $1.6B | $707M | $103M | $75M | ($411M) | ($599M) | ($555M) | $42M | $134M | ($705M) | ($599M) | ($426M) | ($385M) | ($200M) |
| Beneficio por acción (EPS) | $17.18 | $15.32 | $-2.08 | $13.89 | $12.82 | $9.01 | $10.30 | $4.51 | $8.09 | $1.04 | $-0.46 | $-2.31 | $-3.14 | $-1.98 | $-0.50 | $0.14 | $-3.77 | $-3.70 | $-3.27 | $-3.03 | $-1.83 |
| Acciones en circulación (M) | 256M | 258M | 258M | 260M | 259M | 260M | 263M | 261M | 259M | 253M | 245M | 241M | 235M | 225M | 212M | 209M | 200M | 173M | 141M | 129M | 113M |
Fuente: informes públicos de la empresa (SEC). Verifique en SEC EDGAR antes de confiar en cualquier cifra.
Balances, flujos de caja, datos trimestrales y ratios completos en el visor interactivo de VRTX. /companies/us/VRTX
La información de este sitio es solo educativa e informativa; no constituye asesoramiento de inversión. No se publican precios objetivo ni recomendaciones.
About TickerBase · Data methodology & sources · Privacy · Terms